Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03343639 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
A Phase 2 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT03343639: Completed Phase 2 study, sponsored by Vyne Therapeutics.
NCT03343639 is a Phase 2 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 204 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03343639, a Phase 2 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with plaque psoriasis
Primary Outcome
Worst Itch Numeric Rating Scale (WI-NRS). 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater itch intensity. A 4-point responder is a subject who had at least a 4-point reduction in score between Baseline and Week 8.
Interventions
- DRUG 5 mg Serlopitant Tablets
- DRUG Matching Placebo Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2018-11-12 |
| Phase | Phase 2 |
What the finished NCT03343639 record still lists
NCT03343639 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 2 interventions - of which 5 mg Serlopitant Tablets is the first listed.
NCT03343639 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03343639 about?
NCT03343639 is a clinical study titled "Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis". Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with plaque psoriasis
What is the current status of trial NCT03343639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2017-11-01. Estimated completion is 2018-11-12.
What interventions are being tested in trial NCT03343639?
The interventions under investigation include: 5 mg Serlopitant Tablets (DRUG), Matching Placebo Tablets (DRUG).
Who is sponsoring clinical trial NCT03343639?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03343639's enrollment target sits among peer trials
204 299th of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI